Outset Medical, Inc. (NASDAQ:OM) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Outset Medical, Inc. (NASDAQ:OM) have earned an average recommendation of “Moderate Buy” from the five ratings firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $12.6667.

A number of brokerages have weighed in on OM. Royal Bank Of Canada reissued a “sector perform” rating and set a $7.00 price target on shares of Outset Medical in a research report on Wednesday, December 17th. Wall Street Zen raised Outset Medical from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Stifel Nicolaus set a $14.00 target price on Outset Medical and gave the stock a “buy” rating in a report on Tuesday, November 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a research report on Monday. Finally, BTIG Research reaffirmed a “buy” rating and set a $17.00 price objective on shares of Outset Medical in a research report on Tuesday, December 16th.

Institutional Investors Weigh In On Outset Medical

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Assenagon Asset Management S.A. purchased a new stake in shares of Outset Medical during the 3rd quarter valued at $5,324,000. Woodline Partners LP bought a new position in Outset Medical during the first quarter valued at about $14,663,000. Geode Capital Management LLC grew its position in Outset Medical by 955.9% during the second quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock valued at $7,984,000 after buying an additional 376,196 shares during the period. Pura Vida Investments LLC increased its holdings in Outset Medical by 8,482.4% during the second quarter. Pura Vida Investments LLC now owns 429,120 shares of the company’s stock worth $8,243,000 after buying an additional 424,120 shares during the last quarter. Finally, Parkman Healthcare Partners LLC bought a new stake in Outset Medical in the first quarter worth about $2,556,000.

Outset Medical Price Performance

Shares of OM opened at $3.62 on Wednesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.77 and a current ratio of 7.09. The stock has a 50 day simple moving average of $6.81 and a 200 day simple moving average of $12.66. Outset Medical has a 52-week low of $3.10 and a 52-week high of $25.35. The firm has a market capitalization of $65.70 million, a PE ratio of -0.28 and a beta of 2.03.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.